Immuron Ltd（IMRN）財務資料IMRNImmuron Ltd

Immuron Ltd (IMRN) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is HyperImmune Products, accounting for 100.0% of total sales, equivalent to AUD 1.22M. Other significant revenue streams include Travelan and Protectyn. Understanding this composition is critical for investors evaluating how IMRN navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Immuron Ltd maintains a gross margin of 63.42%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -47.16%, while the net margin is -45.86%. These profitability ratios, combined with a Return on Equity (ROE) of -39.68%, provide a clear picture of how effectively IMRN converts its operational activities into shareholder value.

In the context of the broader market, IMRN competes directly with industry leaders such as PBM and PTN. With a market capitalization of $6.71M, it holds a significant position in the sector. When comparing efficiency, IMRN's gross margin of 63.42% stands against PBM's N/A and PTN's 100.00%. Such benchmarking helps identify whether Immuron Ltd is trading at a premium or discount relative to its financial performance.

Immuron reported total revenue of 1,646,330 AUD in Q3 2025, with a gross profit of 1,054,025 AUD. However, the company also reported a net income loss of 1,363,584 AUD, indicating financial struggles despite some revenue growth.